Oct 23 (Reuters) - AstraZeneca Plc has resumed the
U.S. trial of its experimental COVID-19 vaccine after approval
by U.S. regulators, the company said on Friday.
AstraZeneca's U.S. trial was paused on Sept. 6 after
a report of a serious neurological illness, believed to be
transverse myelitis, in a participant in the company's UK trial.
(Reporting by Munsif Vengattil and Carl O'Donnell; Editing by
Anil D'Silva and Rosalba O'Brien)